Summary

United Kingdom precision medicine market is expected to register robust growth in the forecast period, 2023-2027. Precision medicine evaluates the genes and proteins which are present in the body of a patient to design a personalized treatment drug to cure the specific disease. With such discoveries including single nucleotide polymorphism and microarray/ biochips in the field of precision medicine, the market is projected to experience a boom in the upcoming years. Continuous research activities on the human genome are the future of precision medicine and have the potential to upend the medical treatment of individual patients by understanding their genetics, molecular profiles, and clinical characteristics. The growing prevalence of cancer is further escalating the demand for precision medicine for personalized therapeutics and diagnostics which is positively influencing the growth of the market.
The growing Prevalence of CNS Disorders is Projected to Augment the Market Growth
CNS ailments including Alzheimer’s disease, multiple sclerosis, and epilepsy, afflict millions of individuals across the globe which is primarily driving the market growth. Dementia affects more than 50 million individuals worldwide. Alzheimer's disease, the most common kind of dementia, accounts for 60-70 percent of all cases. The growth of the industry is aided by an enhancing focus on targeted therapeutics and the development of individualized medical treatment regimens for persons suffering from CNS illnesses.
Elevating Prevalence of Cancer Across the United Kingdom Drives the Market Growth
The escalating demand for precision medicine methods across developed countries like the UK owing to the rising prevalence of cancer and the increasing number of treatment candidates in clinical trials. This, in turn, is driving the market growth. In addition to this, the rising number of cases of genetic diseases will continue to influence positively the growth of the precision medicine market. With this, the elevating levels of urbanization and inflating level of disposable income are accelerating the growth of the precision medicine market. The growing expenditure on healthcare infrastructure and expanding geriatric population are the major market drivers that support the growth of the precision medicine market. The recent development in technologies including ultra-high throughput sequencing and next-generation sequencing is expected to fuel the growth of the market over the future years.
Extensive R&D Activities are Anticipated to Bolster the Market Growth
The growing number of research and development activities offer lucrative opportunities for the precision medicine market growth. The enhancing focus of manufacturers on the adoption of upgraded technologies and the rise in the number of emerging economies will opportunities for the precision medicine market growth in the upcoming years.
Market Segmentation
The United Kingdom precision medicine devices market is segmented into products and services, technology, application, end-user, regional distribution, and competitive landscape. Based on products and services, the market is segmented into precision medicine platforms, precision medicine tools, and precision medicine services. Based on technology, the market is segmented into big data analytics, artificial intelligence, bioinformatics, whole genome sequencing, companion diagnostics, next-generation sequencing (NGS), and others). Based on application, the market is categorized into oncology, immunology, cardiology, neurology, respiratory, and others. Based on end users, the market is divided into pharmaceutical and biotechnology companies, healthcare IT, diagnostic companies, clinical research organizations, and research institutes. To analyze the market based on the region, the United Kingdom precision medicine devices market is studied in major regions namely London, Southeast, East Anglia, Scotland, Southwest, East Midlands, and Yorkshire & Humberside.
Market Players
Thermo Fischer Scientific United Kingdom, Qiagen Manchester Limited, Illumina Cambridge Limited, Quest Diagnostic Limited, Agilent Technologies UK Limited, GlaxoSmithKline Plc., and Roche Diagnostics Limited are the significant market players operating in United Kingdom precision medicine devices market.

Report Scope:
In this report, United Kingdom precision medicine devices market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• United Kingdom Precision Medicine Devices Market, By Product and Services:
o Precision Medicine Platforms
o Precision Medicine Tools
o Precision Medicine Services
• United Kingdom Precision Medicine Devices Market, By Technology:
o Big Data Analytics
o Artificial Intelligence
o Bioinformatics
o Whole Genome Sequencing
o Companion Diagnostics
o Next Generation Sequencing (NGS)
o Others
• United Kingdom Precision Medicine Devices Market, By Application:
o Oncology
o Immunology
o Cardiology
o Neurology
o Respiratory
o Others
• United Kingdom Precision Medicine Devices Market, By End User:
o Pharmaceutical and Biotechnology Companies
o Healthcare IT
o Diagnostic Companies
o Clinical Research Organization
o Research Institutes
• United Kingdom Precision Medicine Devices Market, By Region:
o London
o Southeast
o East Anglia
o Scotland
o Southwest
o East Midlands
o Yorkshire & Humberside
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in United Kingdom precision medicine devices market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
o Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents